CardioGenics (CGNH) 10-Q 2012 Q3 Quarterly report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

þ Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended July 31, 2012.

£ Transition report under Section 13 or 15(d) of the Exchange Act

For the transition period from                                to                             .

Commission file number 000-28761

CARDIOGENICS HOLDINGS INC.

(Exact name of registrant as specified in its Charter)

Nevada (State or other jurisdiction of incorporation or organization) 88-0380546 (I.R.S. Employer Identification No.)

6295 Northam Drive, Unit 8

Mississauga, Ontario L4V 1WB

(Address of Principal Executive Offices)

(905) 673-8501

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the Issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yesþ       Noo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer and “smaller reporting company” in Rule 12b-2 or the Exchange Act. (Check one):

Large Accelerated filer	£	Accelerated Filer	o
Non-Accelerated Filer	¨	Smaller Reporting Company	þ

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)

Yeso       Noþ

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    

Yes þ       No o

As of September 7, 2012 the Registrant had the following number of shares of its capital stock outstanding: 31,449,239 shares of Common Stock and 1 share of Series 1 Preferred Voting Stock, par value $0.0001, representing 14 exchangeable shares of the Registrant’s subsidiary, CardioGenics ExchangeCo Inc., which are exchangeable into 24,176,927 shares of the Registrant’s Common Stock.

CARDIOGENICS HOLDINGS INC.

FORM 10-Q

For the Quarter Ended July 31, 2012

INDEX

	Page
Part I. Financial Information	2
Item 1: Financial Statements (Unaudited)	2
Condensed Consolidated Balance Sheets at July 31, 2012 (Unaudited) and October 31, 2011	2
Condensed Consolidated Statements of Operations (Unaudited) for the Three and Nine Months ended July 31, 2012 and 2011 and Cumulative from November 20, 1997 (Date of Inception) to July 31, 2012	3
Condensed Consolidated Statement of Changes in Equity (Deficiency) (Unaudited) for the Nine Months ended July 31, 2012	4
Condensed Consolidated Statements of Cash Flows (Unaudited) for the Nine Months ended July 31, 2012 and 2011 and Cumulative from November 20, 1997 (Date of Inception) to July 31, 2012	5
Notes to Condensed Consolidated Financial Statements (Unaudited)	6
Item 2: Management’s Discussion and Analysis	10
Item 3: Quantitative and Qualitative Disclosures About Market Risk	14
Item 4: Controls and Procedures	14

Part II. Other Information	15
Item 1: Legal Proceedings	15
Item 1A: Risk Factors	16
Item 2: Unregistered Sales of Equity Securities and Use of Proceeds	16
Item 3: Defaults Upon Senior Securities	16
Item 4: Removed and Reserved	16
Item 5: Other Information	16
Item 6: Exhibits	16
Signatures	17
EX-31.1: CERTIFICATION	18
EX-31.2: CERTIFICATION	18
EX-32.1: CERTIFICATIONS	18

CardioGenics Holdings Inc.

(A Development Stage Company)

Condensed Consolidated Balance Sheets

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

	July 31,			October 31,
	2012			2011
	(Unaudited)			(Note 2)
Assets
Current Assets
Cash and Cash Equivalents	$	72,732		$	669,202
Accounts Receivable		256			9,002
Deposits and Prepaid Expenses		51,222			51,541
Refundable Taxes Receivable		36,234			35,191
Investment Tax Credits Receivable		156,177			187,497
		316,621			952,433
Property and Equipment, net		72,567			82,308
Patents, net		131,287			130,732
		203,854			213,040
Total Assets	$	520,475		$	1,165,473
Liabilities and  Equity
Current Liabilities
Accounts Payable and Accrued Expenses	$	646,059		$	596,692
Funds Held in Trust for Redemption of Class B Common Shares		4			4
Current Portion of Capital Lease Obligation		7,490			25,711
Due to Shareholders		262,500			▬
		916,053			622,407
Long Term Liabilities
Capital Lease Obligation, net of current portion		▬			2,630
Total Liabilities		916,053			625,037
Commitments and Contingent Liabilities
Equity
Preferred stock; par value $.0001 per share, 5,000,000 shares authorized, 1 issued and outstanding as at July 31, 2012 and October 31, 2011		▬			▬
Common stock; par value $.00001 per share; 65,000,000 shares authorized, 31,449,239 and 31,237,262 common shares and 24,176,927 and 24,388,904 exchangeable shares issued and outstanding as at July 31, 2012 and October 31, 2011 respectively		540			540
Additional paid-in capital		41,774,001			41,774,001
Deficit accumulated during development stage		(41,675,280	)		(40,731,174	)
Accumulated other comprehensive loss		(159,491	)		(173,407	)
Total CardioGenics Holdings Inc. equity		(60,230	)		869,960
Non-controlling interest		(335,348	)		(329,524	)
Total equity (deficiency)		(395,578	)		540,436
Total liabilities and  equity	$	520,475		$	1,165,473

See notes to condensed consolidated financial statements. 

2

CardioGenics Holdings Inc.

(A Development Stage Company)

Condensed Consolidated Statements of Operations (unaudited)

For the Three and Nine Months Ended July 31, 2012 and 2011 and

Cumulative from November 20, 1997 (Date of Inception) to July 31, 2012

													Cumulative
													From
													November
													20, 1997
													(Date of
	For the three months Ended						For the nine months Ended						Inception) to
	July 31,						July 31,						July 31,
	2012			2011			2012			2011			2012
Revenue	$	—		$	6,400		$	1,136		$	6,400		$	10,012
Operating Expenses
Depreciation of Property and Equipment		4,541			5,409			13,635			14,938			215,074
Amortization of Patent Application Costs		1,215			1,090			3,775			3,222			16,186
Write-off of Patent Application Costs		▬			▬			▬			▬			214,625
General and Administrative		154,869			278,314			516,357			958,963			8,105,047
Write-off of Goodwill		▬			▬			▬			▬			12,780,214
Research and Product Development, Net of Investment Tax Credits		73,715			141,206			422,453			534,776			4,136,211
Cost of Settlement of Lawsuit		▬			1,753,800			▬			1,753,800			1,753,800
Total operating expenses		234,340			2,179,819			956,220			3,265,699			27,221,157
Operating Loss		(234,340	)		(2,173,419	)		(955,084	)		(3,259,299	)		(27,211,145	)
Other Expenses (Income)
Interest Expense and Bank Charges, Net		5,402			6,440			14,887			15,340			2,151,523
Loss on Change in Value of Derivative Liability		▬			▬			▬			▬			12,421,023
Loss (Gain) on Foreign Exchange Transactions		(915	)		7,149			(20,041	)		139,312			189,224
Total other expenses (income)		4,487			13,589			(5,154	)		154,652			14,761,770
Loss from Continuing Operations		(238,827	)		(2,187,008	)		(949,930	)		(3,413,951	)		(41,972,915	)
Discontinued Operations
Gain  on Sale of Subsidiary		▬			▬			▬			▬			90,051
Loss from Discontinued Operations		▬			▬			▬			▬			(127,762	)
Net Loss		(238,827	)		(2,187,008	)		(949,930	)		(3,413,951	)		(42,010,626	)
Net Loss attributable to non-controlling interest		(1,393	)		(14,638	)		(5,824	)		(22,850	)		(335,348	)
Net Loss attributable to CardioGenics Holdings Inc.	$	(237,434	)	$	(2,172,370	)	$	(944,106	)	$	(3,391,101	)	$	(41,675,278	)
Basic and Fully Diluted Net Loss per Common Share attributable to CardioGenics Holdings Inc. Shareholders	$	(0.01	)	$	(0.04	)	$	(0.02	)	$	(0.06	)
Weighted-average shares of Common Stock outstanding		55,626,166			54,626,166			55,626,166			54,256,408

See notes to condensed consolidated financial statements.

3

CardioGenics Holdings Inc.

(A Development Stage Company)

Condensed Consolidated Statements of Changes in Equity (unaudited)

For the nine months ended July 31, 2012

							Deficit
							Accumulated
							During			Accumulated
					Additional		the			Other						Total
	Common Stock				Paid-in		Development			Comprehensive			Noncontrolling			Equity
	Shares		Amount		Capital		Stage			Income (Loss)			Interest			(Deficiency)
Balance October 31, 2011		55,626,166	$	540	$	41,774,001	$	(40,731,174	)	$	(173,407	)	$	(329,524	)	$	540,436
Net loss attributable to noncontrolling interest														(5,824	)		(5,824	)
Comprehensive Income (Loss):
Net Loss								(944,106	)								(944,106	)
Other Comprehensive Income
Currency Translation Adjustment											13,916						13,916
Total Comprehensive (Loss)																	(930,190	)
Balance at July 31, 2012		55,626,166	$	540	$	41,774,001	$	(41,675,280	)	$	(159,491	)	$	(335,348	)	$	(395,578	)

See notes to condensed consolidated financial statements.

4

CardioGenics Holdings Inc.

(A Development Stage Company)

Condensed Consolidated Statements of Cash Flows (unaudited)

Nine Months Ended July 31, 2012 and 2011 and

Cumulative from November 20, 1997 (Date of Inception) to July 31, 2012

							Cumulative from
							November 20, 1997
	Nine Months Ended						(Date of Inception)
	July 31,						To July 31,
	2012			2011			2012
Cash flows from operating activities
Net Loss for the Period	$	(949,930	)	$	(3,413,951	)	$	(42,010,626	)
Adjustments to reconcile net loss for the period to net cash used in operating activities
Depreciation of Property and Equipment		13,635			14,938			215,074
Amortization of Patent Application Costs		3,775			3,222			16,186
Write-off of Patent Application Costs		▬			▬			214,625
Write-off of Goodwill		▬			▬			12,780,214
Amortization of Deferred Debt Issuance Costs		▬			▬			511,035
Loss on Extinguishment of Debt		▬			▬			275,676
Loss on Change in Value of Derivative Liability		▬			▬			12,421,023
Interest Accrued and Foreign Exchange Loss on Debt		▬			▬			922,539
Unrealized Foreign Currency Exchange Gains		▬			▬			25,092
Beneficial Conversion Charge included in Interest Expense		▬			▬			452,109
Re-pricing of Options for Services Rendered		▬			163,750			163,750
Common Stock and Warrants issued on Settlement Of Lawsuit		▬			▬			1,653,800
Common Stock Issued as Employee or Officer/Director Compensation		▬			▬			2,508,282
Common Stock Issued for Services Rendered		▬			100,000			2,726,262
Stock Options Issued for Services Rendered		▬			▬			192,238
Stock Options Issued to Directors and Committee Chairman		▬			▬			54,582
Changes in Operating Assets and Liabilities, Net of Acquisition
Accounts Receivable		8,746			(6,400	)		(256	)
Share Subscriptions Receivable		▬			115,000			▬
Deposits and Prepaid Expenses		319			38,673			(50,433	)
Refundable Taxes Receivable		(1,043	)		(16,101	)		(35,370	)
Investment Tax Credits Receivable		31,320			156,482			(136,115	)
Accounts Payable and Accrued Expenses		49,370			1,835,883			(121,850	)
Advances		▬			▬			131
Cash used in operating activities		(843,808	)		(1,008,504	)		(7,222,032	)
Cash flows from investing activities
Cash Acquired from Acquisition		▬			▬			195,885
Purchase of Property and Equipment		(3,893	)		(12,772	)		(223,559	)
Patent Application Costs		(4,329	)		▬			(318,899	)
Cash used in investing activities		(8,222	)		(12,772	)		(346,573	)
Cash flows from financing activities
Repayment of Capital Lease Obligations		(20,851	)		(5,139	)		(36,427	)
Due to Shareholders		262,500			▬			262,500
Due to Director		▬			(15,149	)		725,330
Issue of Debentures		▬			▬			1,378,305
Issue of Common Shares on Exercise of Stock options		▬			2,750			2,781
Issue of Common Shares on Exercise of Warrants		▬			▬			45,652
Issue of Common Shares for Cash		▬			359,411			5,624,169
Refund of Share Subscription		▬			(15,378	)		(15,000	)
Redemption of 10% Senior Convertible Debentures		▬			▬			(394,972	)
Cash provided by financing activities		241,649			326,495			7,592,338
Effect of foreign exchange on cash and cash equivalents		13,911			(32,327	)		48,999
Cash and Cash Equivalents
Increase (decrease) in cash and cash equivalents during the period		(596,470	)		(727,108	)		72,732
Beginning of Period		669,202			1,844,752			▬
End of Period	$	72,732		$	1,117,644		$	72,732

See notes to condensed consolidated financial statements.

5

CardioGenics Holdings Inc.

(A Development Stage Company)

Notes to Condensed Consolidated Financial Statements (unaudited)

1. Nature of Business

CardioGenics Inc. (“CardioGenics”) was incorporated on November 20, 1997 in the Province of Ontario, Canada, and carries on the business of development and commercialization of diagnostic test products to the In Vitro Diagnostics testing market. CardioGenics has several test products that are in various stages of development.

CardioGenics’ business is that of a development-stage company, with a limited history of operations and whose revenues, to date, have been primarily comprised of grant revenue and Scientific Research Tax Credits from government agencies. There can be no assurance that the Company will be successful in obtaining regulatory approval for the marketing of any of the existing or future products that the Company will succeed in developing.

On October 27, 2009, the name of the Company was changed from JAG Media Holdings, Inc. to CardioGenics Holdings Inc.

2. Basis of Presentation

In the opinion of management, the unaudited condensed interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary to present fairly the condensed interim consolidated financial position of CardioGenics Holdings Inc. and its subsidiaries under generally accepted accounting principles in the United States (“US GAAP”) as of July 31, 2012, its results of operations for the three and nine months ended July 31, 2012 and 2011, and the period from November 20, 1997 (date of inception) to July 31, 2012, changes in equity for the nine months ended July 31, 2012 and cash flows for the nine months ended July 31, 2012 and 2011, and the period from November 20, 1997 (date of inception) to July 31, 2012. CardioGenics Holdings Inc and its subsidiaries are referred to together herein as the “Company”. Pursuant to rules and regulations of the SEC, certain information and disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted from these consolidated financial statements unless significant changes have taken place since the end of the most recent fiscal year. Accordingly, these condensed interim consolidated financial statements should be read in conjunction with the consolidated financial statements, notes to consolidated financial statements and the other information in the audited consolidated financial statements of the Company as of October 31, 2011 and 2010 (the “Audited Financial Statements”) included in the Company’s Form 10-K/A that was previously filed with the SEC on April 13, 2012 and from which the October 31, 2011 consolidated balance sheet was derived.

The results of the Company’s operations for the three and nine months ended July 31, 2012 are not necessarily indicative of the results of operations to be expected for the full year ending October 31, 2012.

The condensed interim consolidated financial statements have been prepared using the accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.

The Company has incurred operating losses and has experienced negative cash flows from operations since inception. The Company has an accumulated deficit at July 31, 2012 of approximately $41.7 million. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The Company has funded its activities to date almost exclusively from debt and equity financings. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

6

CardioGenics Holdings Inc.

(A Development Stage Company)

Notes to Condensed Consolidated Financial Statements (unaudited)

The Company will continue to require substantial funds to continue research and development, including preclinical studies and clinical trials of its products, and to commence sales and marketing efforts, if the FDA and other regulatory approvals are obtained. In order to meet its operating cash flow requirements Management’s plans include financing activities such as private placements of its common stock and issuances of convertible debt instruments. Management is also actively pursuing industry collaboration activities including product licensing and specific project financing.

While the Company believes it will be successful in obtaining the necessary financing to fund its operations, meet revenue projections and manage costs, there are no assurances that such additional funding will be achieved and that it will succeed in its future operations. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue in existence.

3. Summary of Significant Accounting Policies.

Recent Accounting Pronouncements

In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities. ASU 2011-11 requires an entity to disclose information about offsetting and related arrangements to enable users of financial statements to understand the effect of those arrangements on its financial position, and to allow investors to better compare financial statements prepared under U.S. GAAP with financial statements prepared under International Financial Reporting Standards (IFRS). The new standards are effective for annual periods beginning January 1, 2013, and interim periods within those annual periods. Retrospective application is required. The Company will implement the provisions of ASU 2011-11 beginning in fiscal 2014.

In June 2011, the FASB issued ASU 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income. Under this ASU, an entity will have the option to present the components of net income and comprehensive income in either one or two consecutive financial statements. The ASU eliminates the option in U.S. GAAP to present other comprehensive income in the statement of changes in equity. An entity should apply the ASU retrospectively. Early adoption is permitted. The Company plans to implement the provisions of ASU 2011-05 by presenting a separate statement of other comprehensive income following the statement of operations beginning in fiscal 2013.

4. Income Taxes

Based on the Company’s evaluation, management has concluded that there are no significant tax reserves requiring recognition in the condensed interim consolidated financial statements.

The Company has incurred losses in Canada since inception, which have generated net operating loss carryforwards for income tax purposes. The net operating loss carryforwards arising from Canadian sources as of July 31, 2012, approximated $6,362,000 (2011 - $5,495,000) which will expire from 2013 through 2032. All fiscal years have been assessed as originally filed in Canadian jurisdictions.

As of July 31, 2012, the Company had net operating loss carryforwards from US sources of approximately $40,647,000 available to reduce future US Federal taxable income which will expire from 2019 through 2032. Returns for the years 2008 through 2011 are yet to be filed.

For the nine months ended July 31, 2012 and 2011, the Company’s effective tax rate differs from the statutory rate principally due to the net operating losses for which no benefit was recorded.

7

CardioGenics Holdings Inc.

(A Development Stage Company)

Notes to Condensed Consolidated Financial Statements (unaudited)

5. Due to Shareholders

In February 2012 the Company received $262,500 for the subscription of 1,050,000 of the Company’s common stock. To date, the common stock has not been issued to the subscribers.

6. Stock Based Compensation

Stock-based employee compensation related to stock options for the nine months ended July, 2012 and 2011 amounted to $-0-.

The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan:

			Weighted
			Average
			Exercise
	Options		Price
Outstanding – October 31, 2010		305,000	$	2.34
Granted		▬		▬
Forfeited/Expired		▬		▬
Exercised		275,000	$	0.01
Outstanding – October 31, 2011		30,000	$	0.90
Granted		▬		▬
Forfeited/Expired		▬		▬
Exercised		▬		▬
Outstanding – July 31, 2012		30,000	$	0.90

Options typically vest immediately at the date of grant. As such, the Company does not have any unvested options or unrecognized compensation expense at July 31, 2012.

8

CardioGenics Holdings Inc.

(A Development Stage Company)

Notes to Condensed Consolidated Financial Statements (unaudited)

7. Warrants

Outstanding warrants are as follows: 

	July 31, 2012		October 31, 2011
Issued to subscribers to the debenture financing of 2003 and its related extension entitling the holder to purchase 1 common share of the Company at an exercise price of $0.47 per common share up to and including July 31, 2012 expired unexercised		▬		2,046,808
Issued to subscribers to the debenture financing of 2004 and its related extension entitling the holder to purchase 1 common share in the Company at an exercise price of $0.47 per common share up to and including July 31, 2012 expired unexercised		▬		1,021,654
Issued to agents for the debenture financings of 2003 and 2004 entitling the holder to  purchase 1 common share in the Company at an exercise price of $0.47 per common share up to and including July 31, 2012 expired unexercised		▬		208,417
Issued to former employee entitling the holder to purchase 1 common share in the Company at an exercise price of $0.47 per common share up to and including July 31, 2012 expired unexercised		▬		136,220
Issued to consultants July 31, 2009, entitling the holder to purchase 1 common share of the Company at an exercise price of $0.90 per share up to and including July 31, 2012 expired unexercised		▬		104,785
Issued to consultant August 1, 2009, entitling the holder to purchase 1 common share in the company at an exercise price of $0.90 per common share up to and including July 31, 2017		287,085		287,085
Issued to Flow Capital Advisors Inc. on settlement of lawsuit in August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.30 per common share up to and including August 23, 2016		250,000		250,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including August 23, 2016		250,000		250,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016		500,000		500,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $1.00 per common share up to and including August 23, 2016		500,000		500,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016		500,000		500,000
Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.10 per common share up to and including March 20, 2013		1,500,000		1,500,000
Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.34 per common share up to and including March 20, 2013		1,500,000		1,500,000
Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including March 20, 2013		1,000,000		1,000,000
Total Warrants outstanding		6,287,085		9,804,969

8. Issuance of Common Stock

During the nine months ended July 31, 2012, the Company issued no common shares, except for 211,977 common shares which were issued in exchange for 211,977 exchangeable shares.

9. Net Loss per Share

The following table sets forth the computation of weighted-average shares outstanding for calculating basic and diluted earnings per share (EPS):

	Three Months Ended July 31,				Nine Months Ended July 31,
	2012		2011		2012		2011
Weighted-average shares - basic		55,626,166		54,626,166		55,626,166		54,256,408
Effect of dilutive securities		▬		▬		▬		▬
Weighted-average shares - diluted		55,626,166		54,626,166		55,626,166		54,256,408

9

CardioGenics Holdings Inc.

(A Development Stage Company)

Notes to Condensed Consolidated Financial Statements (unaudited)

Basic EPS and diluted EPS for the three and nine months ended July, 2012 and 2011 have been computed by dividing the net loss available to common stockholders for each respective period by the weighted average shares outstanding during that period. All outstanding options, warrants and shares to be issued upon the exercise of the outstanding options and warrants representing 6,317,085 and 4,131,974 incremental shares respectively have been excluded from the nine months ended July 31, 2012 and 2011 computation of diluted EPS as they are antidilutive given the net losses generated.

10. Commitments and Contingent Liabilities

Lawsuits

On April 22, 2009, the Company was served with a statement of claim from a former employee claiming compensation for wrongful dismissal and ancillary causes of action including payment of monies in realization of his investment in the Company, with an aggregate claim of $514,000. The Company considers all the claims to be without any merit, has already delivered a statement of defense and intends to vigorously defend the action. If the matter eventually proceeds to trial, the Company does not expect to be found liable on any ground or for any cause of action.

11. Supplemental Disclosure of Cash Flow Information

	For the Nine Months Ended
	July 31
	2012		2011
Cash paid during the year for:
Interest	$	11,420	$	7,480
Income taxes	$	▬	$	▬

10

Item 2.  Management’s Discussion and Analysis

You should read this Management’s Discussion and Analysis (“MD&A”) in combination with the accompanying unaudited condensed interim consolidated financial statements and related notes as well as the audited consolidated financial statements and the accompanying notes to the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) included within the Company’s Annual Report on Form 10-K/A filed on April 13, 2012.

Our discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed interim consolidated financial statements, which have been prepared in accordance with U.S. GAAP for interim financial statements filed with the Securities and Exchange Commission.

Critical Accounting Policies and Estimates

The preparation of these unaudited condensed interim consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to accounts receivable, equipment, stock-based compensation, income taxes and contingencies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

The accounting policies and estimates used as of October 31, 2011, as outlined in our previously filed Form 10-K/A, have been applied consistently for the nine months ended July 31, 2012.

Related Party Transactions

During the nine months ended July 31, 2012, we utilized advances from shareholders totaling $262,500 for the subscription of 1,050,000 of the Company’s common stock. To date, the common stock has not been issued to the subscribers.

Off-Balance Sheet arrangements

We are not party to any off-balance sheet arrangements.

Results of operations

Nine months ended July 31, 2012 as compared to nine months ended July 31, 2011

	Nine Months
	Ended July 31,
	2012			2011		$ Change
Revenue	$	1,136		$	6,400	$	(5,264	)
Operating expenses:
Depreciation of property and equipment		13,635			14,938		(1,303	)
Amortization of patent application costs		3,775			3,222		553
General and administrative expenses		516,357			958,963		(442,606	)
Research and product development, net of investment tax credits		422,453			534,776		(112,323	)
Cost of settlement of lawsuit		▬			1,753,800		(1,753,800	)
Total operating expenses		956,220			3,265,699		(2,309,479	)
Operating Loss		955,084			3,259,299		(2,304,215	)
Other expenses (income):
Interest expense and bank charges, net		14,887			15,340		(453	)
Loss (gain) on foreign exchange		(20,041	)		139,312		(159,353	)
Net loss	$	949,930		$	3,413,951	$	(2,464,021	)

Revenues

During the nine months ended July 31, 2012 and 2011 we generated revenues of 2012 - $1,136 and 2011 – $6,400 respectively from sales of paramagnetic beads. We anticipate marginal additional revenues from said sales during the balance of the year. 

Operating expenses

Operating expenses include the costs to a) develop and patent a method for controlling the delivery of compounds to a chemical reaction; b) develop the QL Care Analyzer, a small, automated, robust and proprietary point of care (“POC”) testing device; and, c) customize paramagnetic beads through our proprietary method which improves their light collection. In addition, the Company is in the process of adapting test products for the POC for a disposable, single-use cartridge format. Detailed manufacturing specifications and costing have been created and custom manufacturers have been sourced.

11

General and administrative expenses

General and administrative expenses consist primarily of compensation to officers, occupancy costs, professional fees, listing costs and other office expenses. The decrease in general and administrative expenses is attributable primarily to a decrease in consulting fees and a charge of 2012 – Nil and 2011 - $163,750 due to re-pricing of options.

Research and product development, net of investment tax credits

Research and development expenses consist primarily of salaries and wages paid to officers and employees engaged in those activities and supplies consumed therefor. The decrease in research and development expenses is attributable primarily to the decrease in staff engaged in R&D and the inclusion of a Scientific Tax Credit from Canadian tax authorities of 2012 - $60,000 and 2011 – Nil.

Cost of settlement of lawsuit

On August 17, 2011, the Company and Flow Capital Advisors Inc. participated in a court mandated mediation session wherein the parties agreed to a settlement of all claims.  On August 23, 2011, the Company’s Board of Directors approved the settlement.  As a result, the financial statements at July 31, 2011 reflect a charge of $1,753,800 for the cost of settlement of lawsuit.

Three months ended July 31, 2012 as compared to three months ended July 31, 2011

	Three Months
	Ended July 31,
	2012			2011		$ Change
Revenue	$	▬		$	6,400	$	(6,400	)
Operating expenses:
Depreciation of property and equipment		4,541			5,409		(868	)
Amortization of patent application costs		1,215			1,090		125
General and administrative expenses		154,869			278,314		(123,445	)
Research and product development, net of investment tax credits		73,715			141,206		(67,491	)
Cost of settlement of lawsuit		▬			1,753,800		(1,753,800	)
Total operating expenses		234,340			2,179,819		(1,945,479	)
Operating Loss		234,340			2,173,419		(1,939,079	)
Other expenses (income):
Interest expense and bank charges, net		5,402			6,440		(1,038	)
Loss (gain) on foreign exchange		(915	)		7,149		(8,064	)
Net loss	$	238,827		$	2,187,008	$	(1,948,181	)

Revenues

During the three months ended July 31, 2012 and 2011 we generated revenues of 2012 - NIL and 2011 – $6,400 respectively from sales of paramagnetic beads.

12

Operating expenses

Operating expenses include the costs to a) develop and patent a method for controlling the delivery of compounds to a chemical reaction; b) develop the QL Care Analyzer, a small, automated, robust and proprietary point of care (“POC”) testing device; and, c) customize paramagnetic beads through our proprietary method which improves their light collection. In addition, the Company is in the process of adapting test products for the POC for a disposable, single-use cartridge format. Detailed manufacturing specifications and costing have been created and custom manufacturers have been sourced.

General and administrative expenses

General and administrative expenses consist primarily of compensation to officers, occupancy costs, professional fees, listing costs and other office expenses. The decrease in general and administrative expenses is attributable primarily to a decrease in consulting fees.

Research and product development, net of investment tax credits

Research and development expenses consist primarily of salaries and wages paid to officers and employees engaged in those activities and supplies consumed therefor. The decrease in research and development expenses is attributable primarily to the decrease in staff engaged in R&D and the inclusion of a Scientific Tax Credit from Canadian tax authorities of 2012 - $60,000 and 2011 – Nil.

Cost of settlement of lawsuit

On August 17, 2011, the Company and Flow Capital Advisors Inc. participated in a court mandated mediation session wherein the parties agreed to a settlement of all claims.  On August 23, 2011, the Company’s Board of Directors approved the settlement.  As a result, the financial statements at July 31, 2011 reflect a charge of $1,753,800 for the cost of settlement of lawsuit.

Liquidity and Capital Resources

We have not generated significant revenues since inception. We incurred a net loss of approximately $950,000 and a cash flow deficiency from operating activities of approximately $844,000 for the nine months ended July 31, 2012. We have not yet established an ongoing source of revenues sufficient to cover our operating costs and allow us to continue as a going concern.  We have funded our activities to date almost exclusively from debt and equity financings.  These matters raise substantial doubt about our ability to continue as a going concern.

We will continue to require substantial funds to continue research and development, including preclinical studies and clinical trials of our products, and to commence sales and marketing efforts.  Our plans include financing activities such as private placements of our common stock and issuances of convertible debt instruments.  We are also actively pursuing industry collaboration activities including product licensing and specific project financing.

We believe we will be successful in obtaining the necessary financing to fund our operations, meet revenue projections and manage costs; however, there are no assurances that such additional funding will be achieved and that we will succeed in our future operations.

Seasonality

We do not believe that our business is subject to seasonal trends or inflation. On an ongoing basis, we will attempt to minimize any effect of inflation on our operating results by controlling operating costs and whenever possible, seeking to insure that subscription rates reflect increases in costs due to inflation.

Recent Accounting Pronouncements

The FASB had issued certain accounting pronouncements as of July 31, 2012 that will become effective in subsequent periods; however, we do not believe that any of those pronouncements would have significantly affected our financial accounting measurements or disclosures had they been in effect during the nine months ended July 31, 2012 and 2011 or that they will have a significant effect at the time they become effective.

13

Item 3.    Quantitative and Qualitative Disclosure About Market Risk

N/A.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

In connection with the preparation of this Quarterly Report on Form 10-Q for the quarterly period ended July 31, 2012, our management, including our principal executive officer and principal financial officer, carried out an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (“Exchange Act”). Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective as of July 31, 2012.

Management’s Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate disclosure controls and procedures and internal control over financial reporting (as defined in the Exchange Act) to provide reasonable assurance regarding the reliability of our financial reporting and preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. A control system, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Because of the inherent limitations in all control systems, internal controls over financial reporting may not prevent or detect misstatements. The design and operation of a control system must also reflect that there are resource constraints and management is necessarily required to apply its judgment in evaluating the cost-benefit relationship of possible controls.

Our management assessed the effectiveness of our disclosure controls and procedures and internal control over financial reporting for the quarter ended July 31, 2012 based on the criteria established inInternal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on such assessment, our management concluded that during the period covered by this report, our disclosure controls and procedures and internal control over financial reporting were not effective. Management has identified the following material weaknesses in our disclosure controls and procedures and internal control over financial reporting:

•  lack of documented policies and procedures;

• there is no effective separation of duties, which includes monitoring controls, between the members of management; and,

• lack of resources to account for complex and unusual transactions.

Management is currently evaluating what steps, if any, can be taken in order to address these material weaknesses in light of our current management structure.

14

Changes in Internal Control over Financial Reporting

During the fiscal quarter ended July 31, 2012, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

On April 22, 2009, CardioGenics was served with a statement of claim in the Province of Ontario, Canada, from a prior contractor claiming compensation for wrongful dismissal and ancillary causes of action including payment of monies in realization of his investment in CardioGenics, with an aggregate claim of $514,000.  The Company considers all the claims to be without any merit, has already delivered a statement of defence and intends to vigorously defend the action.  If the matter eventually proceeds to trial, the Company does not expect to be found liable on any ground or for any cause of action.

On January 14, 2010, Flow Capital Advisors Inc. (“Flow Capital”) filed a lawsuit against JAG Media Holdings Inc. in the Circuit Court of the 17^th Judicial Circuit In and For Broward County Florida (Case No. 10001713) (the “Flow Capital State Action”).  Pursuant to this lawsuit, Flow Capital alleges that JAG Media Holdings breached a Non-Circumvention Agreement it had entered into with Flow Capital, dated January 1, 2004. 

On January 15, 2010 Flow Capital filed a lawsuit against CardioGenics Inc., and another defendant in the United States District Court for the Southern District of Florida, Fort Lauderdale Division (Case No. 10-CV-60066-Martinez-Brown) (the “Flow Capital Federal Action”). This lawsuit alleges that CardioGenics (i) breached a Finder’s Fee Agreement in connection with the CardioGenics Acquisition; and (ii) breached a non-circumvention agreement. Flow Capital is claiming that it is entitled to the finder’s fee equal to eight percent (8%) of the JAG Media Holdings shares received by CardioGenics, or the equivalent monetary value of the stock. Plaintiff subsequently amended its complaint to add related tort claims.

Pursuant to applicable federal court rules, the parties to the Flow Capital Federal Action participated in a court mandated mediation session on August 17, 2011 where the parties attempted to settle their disputes. At the mediation, the parties agreed to a settlement of all claims as described below, subject to the approval of the Board of Directors of CardioGenics Holdings Inc., which approval was subsequently obtained. Pursuant to the settlement agreement, Flow Capital agreed to dismiss, with prejudice, the Flow Capital Federal Action and the Flow Capital State Action and CardioGenics agreed to issue Flow Capital 1,000,000 shares of restricted CardioGenics Holdings common stock and warrants to purchase restricted CardioGenics Holdings common stock as follows:

Type of Warrant	Number of Shares	Exercise Price	Vesting Date	Term
Cash Exercise Only	250,000	$0.30/share	immediate	5 years
Cash Exercise Only	250,000	$0.50/share	immediate	5 years
Cash Exercise Only	500,000	$0.75/share	immediate	5 years
Cash Exercise Only	500,000	$1.00/share	immediate	5 years
Cash or Cashless Exercise	500,000	$0.75/share	August 1, 2012	5 years

The restricted shares of common stock and the warrants are subject to the rights and restrictions of Rule 144 and do not have any registration rights. As part of the settlement, the parties also exchanged mutual general releases and CardioGenics Holdings agreed to pay Flow Capital, in three monthly installments, $100,000 for Flow Capital’s legal fees.

On August 23, 2011, the Company’s Board of Directors approved the settlement. As a result, the Company recorded a charge to the Condensed Statement of Operations at July 31, 2011 of $1,753,800 for Cost of Settlement of Lawsuit, which amount is included in Accounts Payable and Accrued Expenses at July 31, 2011.

15

On October 26, 2010 Karver International Inc. filed a lawsuit in the 11^th Judicial Circuit in and for Miami-Dade County, Florida against CardioGenics Holdings Inc. and several other defendants including affiliates, officers and directors of CardioGenics Holdings, Inc. The Plaintiff generally alleges that the named defendants made certain alleged misrepresentations in connection with the purchase of shares of CardioGenics Holdings Inc. On December 20, 2010 CardioGenics Holdings Inc. and other defendants filed a motion to dismiss on the basis that the court lacks personal jurisdiction over most defendants, that an enforceable forum selection clause requires that the action be litigated in Ontario, Canada that the doctrine offorum non conveniens requires dismissal in favor of the Ontario forum, and that the complaint suffers from numerous other technical deficiencies warranting dismissal (e.g., failure to attach documents to the Complaint, failure to plead fraud with particularity, etc.). In addition, prior to the motion being heard, Karver’s attorney filed a motion to withdraw as counsel for Karver. The court granted Karver’s attorney’s motion to withdraw and Karver had until approximately April 26, 2011 to engage new counsel. On April 20, 2011, having not engaged new counsel as of that date, Karver filed with the court a Notice of Voluntary Dismissal Without Prejudice, which dismisses the lawsuit against the named defendants without prejudice to Karver’s rights to recommence the action.

Item 1A. Risk Factors

Not Applicable

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3. Defaults Upon Senior Securities

None

Item 4. (Removed and Reserved)

None

Item 5. Other Information

None

Item 6. Exhibits

31.1 Section 302 Certification of Chief Executive Officer.

31.2 Section 302 Certification of Chief Financial Officer.

32.1 Section 906 Certification of Chief Executive Officer and Chief Financial Officer.

16

SIGNATURES

In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CARDIOGENICS HOLDINGS INC.
Date: September 14, 2012	By:	/s/ Yahia Gawad
		Name:  Yahia Gawad
		Title:  Chief Executive Officer
Date: September 14, 2012	By:	/s/ James Essex
		Name:  James Essex
		Title:  Chief Financial Officer

17

EXHIBIT INDEX

31.1 Section 302 Certification of Chief Executive Officer

31.2 Section 302 Certification of Chief Financial Officer

32.1 Section 906 Certification of Chief Executive Officer and Chief Financial Officer

18